H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU) Jan 15, 2026 06:45AM
Lucid Capital Markets Reiterates Buy Rating on Actuate Therapeutics (ACTU) Jan 6, 2026 02:26PM
Actuate Therapeutics publishes phase II salivary gland cancer data Dec 15, 2025 08:45AM
H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU) Sep 23, 2025 06:37AM
Actuate Therapeutics updates FDA on pancreatic cancer drug trial data Sep 22, 2025 08:45AM


Aug 26, 2025 01:08AM B.Riley Starts Actuate Therapeutics (ACTU) at Buy
Aug 6, 2025 08:45AM Actuate Therapeutics starts pancreatic cancer trial with Incyte, Pittsburgh
Jul 25, 2025 04:03PM Actuate Therapeutics (ACTU) Files for 1.33M Share Offering by Selling Stockholders
Jul 21, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
Jun 20, 2025 08:45AM Actuate Therapeutics (ACTU) Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial
May 22, 2025 05:29PM Actuate Therapeutics (ACTU) announces publication of abstract ahead of ASCO 2025
May 6, 2025 08:01AM Actuate Therapeutics (ACTU) Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of MPC
Apr 22, 2025 09:02AM Craig-Hallum Starts Actuate Therapeutics (ACTU) at Buy
Feb 25, 2025 08:04AM Actuate Therapeutics (ACTU) Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic
Jan 7, 2025 08:03AM Actuate Therapeutics (ACTU) Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Dec 17, 2024 08:02AM Actuate Therapeutics (ACTU) Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Nov 12, 2024 08:04AM Actuate Therapeutics (ACTU) Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
Sep 11, 2024 08:00AM Actuate Therapeutics (ACTU) Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Sep 9, 2024 08:01AM Actuate Therapeutics (ACTU) Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Jul 23, 2024 06:07AM Actuate Therapeutics (ACTU) Announces 2M Share IPO at $8-$10/sh
Jul 19, 2024 08:00AM Actuate Therapeutics (ACTU) Files for 2.78M Share Offering by Selling Stockholders
Jun 11, 2024 07:04AM Actuate Therapeutics (ACTU) Announces 5.56M Share IPO at $8-$10/sh